JP2014512182A5 - - Google Patents

Info

Publication number

JP2014512182A5

JP2014512182A5 JP2014503958A JP2014503958A JP2014512182A5 JP 2014512182 A5 JP2014512182 A5 JP 2014512182A5 JP 2014503958 A JP2014503958 A JP 2014503958A JP 2014503958 A JP2014503958 A JP 2014503958A JP 2014512182 A5 JP2014512182 A5 JP 2014512182A5

Authority

JP

Japan

Prior art keywords

antigen

epitope

compound

composition

antibody

Prior art date

2012-04-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 claims description 56
• 102000036639 antigens Human genes 0.000 claims description 56
• 108091007433 antigens Proteins 0.000 claims description 56
• 150000001875 compounds Chemical class 0.000 claims description 55
• 239000000203 mixture Substances 0.000 claims description 33
• 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 18
• 241001465754 Metazoa Species 0.000 claims description 12
• 239000012678 infectious agent Substances 0.000 claims description 12
• 150000001413 amino acids Chemical class 0.000 claims description 10
• 206010028980 Neoplasm Diseases 0.000 claims description 8
• 208000037797 influenza A Diseases 0.000 claims description 8
• 108020004707 nucleic acids Proteins 0.000 claims description 8
• 102000039446 nucleic acids Human genes 0.000 claims description 8
• 150000007523 nucleic acids Chemical class 0.000 claims description 8
• 201000011510 cancer Diseases 0.000 claims description 7
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
• 208000000474 Poliomyelitis Diseases 0.000 claims description 4
• 230000001580 bacterial effect Effects 0.000 claims description 4
• 230000021615 conjugation Effects 0.000 claims description 4
• 108090000623 proteins and genes Proteins 0.000 claims description 4
• 102000004169 proteins and genes Human genes 0.000 claims description 4
• 230000003612 virological effect Effects 0.000 claims description 4
• 241000702421 Dependoparvovirus Species 0.000 claims description 3
• 208000015181 infectious disease Diseases 0.000 claims description 3
• LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 claims description 2
• DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 claims description 2
• 208000035473 Communicable disease Diseases 0.000 claims description 2
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
• 101710154606 Hemagglutinin Proteins 0.000 claims description 2
• 241000700721 Hepatitis B virus Species 0.000 claims description 2
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
• 241000124008 Mammalia Species 0.000 claims description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 2
• 102000029797 Prion Human genes 0.000 claims description 2
• 108091000054 Prion Proteins 0.000 claims description 2
• 101710176177 Protein A56 Proteins 0.000 claims description 2
• 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 claims description 2
• 239000002671 adjuvant Substances 0.000 claims description 2
• NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 claims description 2
• 239000012634 fragment Substances 0.000 claims description 2
• 230000002538 fungal effect Effects 0.000 claims description 2
• 150000004676 glycans Chemical class 0.000 claims description 2
• 208000002672 hepatitis B Diseases 0.000 claims description 2
• 230000028993 immune response Effects 0.000 claims description 2
• 230000001939 inductive effect Effects 0.000 claims description 2
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical group O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 2
• 231100000252 nontoxic Toxicity 0.000 claims description 2
• 230000003000 nontoxic effect Effects 0.000 claims description 2
• 230000003071 parasitic effect Effects 0.000 claims description 2
• 229920001282 polysaccharide Polymers 0.000 claims description 2
• 239000005017 polysaccharide Substances 0.000 claims description 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
• 230000000069 prophylactic effect Effects 0.000 claims description 2
• 230000001225 therapeutic effect Effects 0.000 claims description 2
• 238000002649 immunization Methods 0.000 claims 1
• 230000003053 immunization Effects 0.000 claims 1
• 238000000746 purification Methods 0.000 claims 1
• 238000000034 method Methods 0.000 description 9
• 239000003814 drug Substances 0.000 description 1